UnitedHealthcare updated MMP391.16 (Pharmacogenomics Testing) on March 1, 2026 to add a review of biomarker evidence in neurology (MDC 01), emphasizing preliminary associations rather than clinically validated tests. Recent studies (2020–2024) report lower serum vitamin B12 in chronic migraine, altered intermediary metabolites across chronic pain conditions, and inflammatory/kynurenine pathway signals in diabetic neuropathic pain, but all suffer from small samples, heterogeneous methods, and limited validation. Systematic reviews cited note inconsistent findings for nutraceuticals (including B12, vitamin D, acetyl‑L‑carnitine, alpha‑lipoic acid) and conclude supplements are not standard management for chronic pain. The policy frames these biomarker and metabolomic signals as hypothesis‑generating and calls for larger, standardized studies before influencing coverage or clinical decision‑making.
March 1, 2026 Revision: Biomarker Evidence Added
Summary of changes in the March 1, 2026 revision to MMP391.16
This revision to UnitedHealthcare's MMP391.16 (Pharmacogenomics Testing) includes updated content in the section discussing biomarkers related to chronic pain, specifically in the neurology and nervous system domain (MDC 01). The policy text now cites multiple recent studies (2020–2024) summarizing evidence on biochemical and metabolomic markers associated with migraine and neuropathic pain, and their limitations.
The update emphasizes that existing studies report associations (e.g., lower serum vitamin B12 in chronic migraine, alterations in intermediary metabolites, and inflammatory markers in diabetic neuropathic pain) but consistently note methodological limitations — small sample sizes, heterogeneity of methods, and lack of validated biomarkers. The revision frames these findings as preliminary and calls out the need for more robust, standardized investigations rather than presenting any biomarker as clinically validated for coverage decisions.
`Vitamin B12` Associations with Episodic and Chronic Migraine
Evidence cited on vitamin B12 and migraine
The policy summarizes a cross-sectional retrospective study (Üstün Özek, 2022) comparing serum vitamin B12 levels in 127 migraine patients and 45 controls. The study found significantly lower mean vitamin B12 levels in migraineurs versus controls (227.30 ± 104.72 ng/L vs 278.44 ± 149.83 ng/L; p = 0.047), with chronic migraine patients having lower levels than those with less frequent migraines (197.50 ± 69.16 ng/L vs 278.56 ± 147.91 ng/L; p = 0.019). The author concluded chronic migraine is associated with lower vitamin B12 and suggested further research.
The policy notes the study limitations reported by the authors: retrospective design, moderate sample size, and lack of related biomarker measurements (folic acid, homocysteine, methylmalonic acid). UnitedHealthcare's inclusion of this study in the policy text frames the finding as associative and exploratory rather than definitive for clinical decision-making or coverage.
Metabolomics Findings and Limitations in Chronic Pain Studies
Metabolomics and candidate metabolite signals across chronic pain conditions
The policy references a systematic review (Aroke et al., 2020) of metabolomic studies in chronic pain conditions (n=18 studies included from 586 identified). Conditions covered included fibromyalgia, osteoarthritis, migraine, and musculoskeletal pain. The review identified altered intermediary metabolites (e.g., succinate, citrate, acetylcarnitine, N-acetylornithine) and amino acids (e.g., glutamine, serine, phenylalanine) associated with chronic pain states but concluded that few metabolites have been validated as biomarkers for pain management.
UnitedHealthcare's document highlights major caveats from the review: heterogeneous metabolomic approaches across studies, inconsistent pain phenotyping (many studies did not quantify pain), and possible counting of multiple articles from the same sample. The policy thus presents metabolomics as an area of preliminary evidence with potential but insufficient validation to support routine clinical application.
Inflammatory Biomarkers in Neuropathic Pain and Evidence on Supplements
Inflammatory and pathway biomarkers in neuropathic pain and role of supplements
The policy includes an observational case-control study (Staats Pires et al., 2020) measuring 14 cytokines in 21 type 1 diabetes patients with neuropathic pain; this study reported increases in neopterin and an elevated kynurenine (KYN) to tetrahydrobiopterin (BH4) ratio, suggesting activation of inflammatory pathways and the kynurenine pathway in diabetic neuropathic pain. The document notes small sample size and non-fasted sampling as study limitations and frames the findings as hypothesis-generating.
In addition, the policy summarizes a 2024 systematic review (Frediani et al.) on diet, supplements, and nonpharmacologic interventions for chronic neuropathic pain. Multiple nutraceuticals and compounds (e.g., vitamin B12, vitamin D, vitamin E, acetyl-l-carnitine, alpha-lipoic acid) were evaluated across diverse neuropathy types with mixed or conflicting results. The policy references the Agency for Healthcare Research and Quality review (McDonagh et al., 2020) to indicate that, overall, supplements are not considered standard management for chronic pain and that pharmacologic agents have only small improvements in some conditions. These inclusions characterize nutritional and inflammatory biomarkers/interventions as having inconsistent evidence and not established as standard care.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.